Study 19 of 20Orforglipron (LY-3502970) literatureThe lancet. Diabetes & endocrinologyTop journal2026
Safety and tolerability of orforglipron in Japanese people with type 2 diabetes.
Not reported in abstract.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpus6
Preclinical · this one
4
Observational
1
Open-label
5
Randomised
4
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Orforglipron (LY-3502970) corpus
ALong-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.The lancet. Diabetes & endocrinology · 2023 · n=401 · 339 participants (85%, 95% CI 80·7-87·8) had at least one treatment-emergent adverse event (TEAE).HumanALong-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.The lancet. Diabetes & endocrinology · 2026HumanDSafety and tolerability of orforglipron in Japanese people with type 2 diabetes.The lancet. Diabetes & endocrinology · 2026—AOrforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026 · n=616 · -7.9% weight change with orforglipron 5.5 mg vs placebo at Week 72, n=118, p<0.001.HumanAHepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.Diabetes, obesity & metabolism · 2026 · Six (0.1%) orforglipron-treated participants had ALT or AST ≥ 3 × ULN and TBIL ≥ 2 × ULN.HumanARole of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.Obesity science & practice · 2023 · n=5766 · -11.8% percent body weight reduction for orforglipron compared to placebo.review